France · Delayed Price · Currency is EUR MedinCell Earnings Call Transcripts
Fiscal Year 2026
-
Olanzapine LAI FDA filing and UZEDY's strong growth drive a 50% revenue increase and improved operating loss. The pipeline advances with AbbVie and Gates Foundation-backed programs, while a robust cash position supports future growth.
Fiscal Year 2025
-
Strong growth is expected from UZEDY and the upcoming long-acting olanzapine, which addresses key safety and compliance issues. Market adoption of LAIs is accelerating, with significant commercial potential in both the US and Europe.
-
A transformative period is underway, with strong UZEDY sales, a robust pipeline led by long-acting olanzapine, and global health initiatives. Profitability is targeted for 2027, with new technologies and partnerships fueling future growth.
-
Three growth engines—UZEDY, olanzapine LAI, and a robust R&D pipeline—are driving rapid expansion, with UZEDY showing strong sales and real-world impact. Major partnerships and a strengthened financial position support a path to profitability by 2027.
-
Revenue tripled to EUR 25.4 million and losses halved, driven by Uzedy's strong launch and pipeline progress. Patent protection was extended, cash reserves strengthened, and operational profitability is targeted for 2027, with major growth expected from Olanzapine LAI.
-
BEPO technology is driving rapid growth in long-acting injectables, with UZEDY and olanzapine LAI leading a robust pipeline. Strategic partnerships, strong financials, and new programs in contraception and malaria position the company for significant royalty and revenue expansion.
-
Long-acting injectable products, led by UZEDY, are driving rapid revenue growth and market share, with strong commercial performance and a robust pipeline supported by major partnerships. Technology advancements and new indications, including bipolar disorder, are set to expand future opportunities.
-
Revenues grew 23% to €8.6M, driven by UZEDY royalties and AbbVie collaboration. Strong cash position and reduced losses support confidence in reaching operating profitability by FY 2026–2027, with major product and partnership milestones ahead.
Fiscal Year 2024
-
2023-2024 was transformative, highlighted by UZEDY's launch, a major AbbVie deal, and reduced net loss. Strong cash position, high-margin revenues, and robust pipeline support a path to profitability by 2026-2027.